Ascendis Pharma A/S ASND

$ 136.02 -1.25%

Annual report 2023
added 12-14-2024

Ascendis Pharma A/S Balance Sheet 2011-2024 | ASND

Annual Balance Sheet Ascendis Pharma A/S

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	-	-	-	-195 M	-180 M	-120 M	-50.2 M	-19.4 M	-14.3 M	-15.3 M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	14.2 M	13.8 M	7 M	6.86 M	5.9 M	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	101 M	88.3 M	31.6 M	-	-	-	-	-	-	-	213 K
Total Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	971 M	826 M	201 M	141 M	79.6 M	38.9 M	23.8 M	13.5 M	11.4 M	12.9 M	20.4 M	23.8 M	22.6 M
Deferred Revenue	-	-	-	363 K	858 K	6.9 M	-	94 K	3.07 M	7.9 M	17.5 M	21.1 M	19.7 M
Retained Earnings	-	-	-	-	-611 M	-393 M	-263 M	159 M	111 M	39.6 M	2.13 M	-1.95 M	-3.2 M
Total Assets	826 M	1.09 B	1.08 B	980 M	677 M	319 M	211 M	190 M	132 M	58.7 M	26.7 M	25.4 M	22.8 M
Cash and Cash Equivalents	392 M	445 M	446 M	585 M	598 M	278 M	195 M	180 M	120 M	-	-	-	-
Book Value	-146 M	263 M	884 M	839 M	597 M	280 M	187 M	177 M	120 M	45.8 M	6.3 M	1.56 M	233 K
Total Shareholders Equity	-	-	884 M	839 M	597 M	280 M	187 M	177 M	120 M	-	-	-	-

All numbers in EUR currency

Quarterly Balance Sheet Ascendis Pharma A/S

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	98 M	95.6 M	94.1 M	89.6 M	85.1 M	27 M	29.1 M	30.8 M	30.7 M	31.5 M	31.5 M	13.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	609 M	101 M	95.6 M	94.1 M	89.6 M	88.3 M	30.1 M	29.1 M	30.8 M	31.6 M	31.5 M	31.5 M	13.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	-	704 M	201 M	212 M	164 M	162 M	141 M	94.5 M	83.5 M	72.6 M	79.6 M	74 M	92.1 M	45.3 M	38.9 M	31 M	36.6 M	17.4 M	23.8 M	-	-	-	13.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	-	-	-	1.38 B	1.08 B	1.21 B	852 M	965 M	980 M	1.05 B	561 M	621 M	677 M	735 M	767 M	762 M	319 M	335 M	369 M	365 M	211 M	-	-	-	190 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	-	-	-	756 M	446 M	693 M	385 M	495 M	585 M	763 M	241 M	534 M	598 M	659 M	690 M	697 M	278 M	310 M	353 M	348 M	195 M	206 M	127 M	158 M	180 M	-	-	-	120 M	-	-	-	50.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-	-	-	673 M	884 M	994 M	687 M	803 M	839 M	952 M	477 M	549 M	597 M	661 M	675 M	717 M	280 M	304 M	332 M	347 M	187 M	-	-	-	177 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-	-	-	673 M	884 M	994 M	687 M	803 M	839 M	952 M	477 M	549 M	597 M	661 M	675 M	717 M	280 M	304 M	332 M	347 M	187 M	202 M	126 M	155 M	177 M	-	-	-	120 M	-	-	-	45.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in EUR currency